1-5 of 5
Elizabeth Garrett-Mayer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years

Pedro Barata, Brian Hobbs, Brian Rini, Channing Paller, Dan Normolle, Elizabeth Garrett-Mayer, Eric Rubin, Gary Rosner, Greg Pond, Jane Perlmutter, Lesley Seymour, Lillian Siu, Nolan Wages, Percy Ivy, Tatiana Prowell, Timothy Yap, David Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A100.
https://doi.org/10.1158/1535-7163.TARG-17-A100
Published: 01 January 2018
View article titled, Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years
Journal Articles

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo

Heather Venant, Mehrdad Rahmaniyan, E. Ellen Jones, Ping Lu, Michael B. Lilly, Elizabeth Garrett-Mayer, Richard R. Drake, Jacqueline M. Kraveka, Charles D. Smith, Christina Voelkel-Johnson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2744–2752.
https://doi.org/10.1158/1535-7163.MCT-15-0279
Published: 06 December 2015
View article titled, The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides <em>In Vitro</em> and <em>In Vivo</em> in another window
Journal Articles

Abstract C62: Phase I trial of ABC294640, a first-in-class sphingosine kinase-2 inhibitor.

Melanie B. Thomas, Carolyn D. Britten, Elizabeth Garrett-Mayer, Steve H. Chin, Tricia A. Bentz, Alan Brisendine, Terri L. Matson, Susan Cusack, Lynn W. Maines, Yan Zhuang, Charles D. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C62.
https://doi.org/10.1158/1535-7163.TARG-13-C62
Published: 01 November 2013
View article titled, Abstract C62: Phase I trial of ABC294640, a first-in-class sphingosine kinase-2 inhibitor.
Journal Articles

The forkhead box-F (FOXF) proteins, important regulators in development, function as tumor suppressors and are epigenetically silenced in breast cancer

Pang-Kuo Lo, Ji Shin Lee, Xiaohui Liang, Tsuyoshi Mori, Jyoti Mehrotra, Mary Jo Fackler, Huiping Zhang, Pedram Argani, Elizabeth Garrett-Mayer, Saraswati Sukumar
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C277.
Published: 01 November 2007
View article titled, The forkhead box-F (FOXF) proteins, important regulators in development, function as tumor suppressors and are epigenetically silenced in breast cancer
Journal Articles

Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

Antonio Jimeno, Gurulingappa Hallur, Audrey Chan, Xiangfeng Zhang, George Cusatis, Fonda Chan, Preeti Shah, Rongbing Chen, Ernest Hamel, Elizabeth Garrett-Mayer, Saeed Khan, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (5): 1509–1516.
https://doi.org/10.1158/1535-7163.MCT-06-0592
Published: 18 May 2007
View article titled, Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein <em>tau</em> is predictive of their activity in pancreatic cancer
Open the PDF for Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein <em>tau</em> is predictive of their activity in pancreatic cancer in another window